Abstracts tagged "Disease Activity"

Abstract Number: 383 • 2016 ACR/ARHP Annual Meeting
Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt
Ana Filipa Mourão^1,2,3, MJ Santos⁴, Mónica Eusébio⁵, Ana Lopes⁶, Filipa Ramos⁷, Manuel Salgado⁸, Paula Estanqueiro⁹, Jose Antonio Melo Gomes¹⁰, Fernando Magalhaes Martins¹¹, José Antonio Costa¹², Ana Carolina Furtado¹³, Ricardo Figueira¹⁴, Iva Brito^15,16,17, Jaime Branco^18,19, João E. Fonseca²⁰ and Helena Canhão²¹, ¹NOVA Medical School - Faculdade Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal, ²Centro Hospitalar Lisboa Ocidental (CHLO- E.P.E.), Lisbon, Portugal, ³Rheumatology, Instituto de Medicina Molecular, Lisbon, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Rheumatology and Metabolic Bone Diseases Department, Santa Maria Hospital,CHLN, Lisbon, Portugal, ⁸Pediatrics, Centro Hospitalar de Coimbra, Coimbra, Portugal, ⁹Pediatrics, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Portuguese Society of Rheumatology, Lisbon, Portugal, ¹²Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹³Rheumatology, Hospital do Divino Espírito Santo, Ponta Delgada, São Miguel, Portugal, ¹⁴Rheumatology, Hospital Dr. Nélio Mendonça, Funchal, Portugal, ¹⁵Rheumatology, Centro Hospitalar do Pirto, Hospital de São João, Porto, Portugal, ¹⁶Rua Raul Caldevilla 126-2 Dto, Hospital Sao Joao, Porto, Portugal, ¹⁷Faculdade de Medicina da Universidade do Porto, Porto, Portugal, ¹⁸Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal, ¹⁹CEDOC, Nova Medical School, Lisbon, Portugal, ²⁰Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, Lisboa, Portugal, ²¹Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
, IL6, IL10, IL17 and TNF in patients with JIA, and detect their relation to disease activity. Results: 281 patients, 66% female, mean age 17.3±10…
Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting
Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Gerrit Wolbink^1,2, Philippe Goupille³, William Sandborn⁴, Hubert Marotte⁵, Denis Mulleman³, David Ternant³, Stéphane Paul⁵, Marc de Longueville⁶, Niels Vande Casteele^4,7, Miren Zamacona⁶, Cathy O'Brien⁶, Tore K. Kvien⁸ and Arthur F. Kavanaugh⁹, ¹Amsterdam Rheumatology Immunology Center (ARC), Reade, Amsterdam, Netherlands, ²Department of Immunopathology, Sanquin, Amsterdam, Netherlands, ³Université François-Rabelais, Tours, France, ⁴Division of Gastroenterology, UC San Diego School of Medicine, La Jolla, CA, ⁵Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁶UCB Pharma, Brussels, Belgium, ⁷KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ⁸Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Division of Rheumatology, Allergy & Immunology, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…
Abstract Number: 953 • 2016 ACR/ARHP Annual Meeting
Comparison of 10-Years Disease Outcomes of Rheumatoid Arthritis Patients with Continued Low Disease Activity on Methotrexate with or without Initial Combination Therapy with Infliximab or Prednisone and Sulfasalazine
SA Bergstra¹, RBM Landewé^2,3, TWJ Huizinga¹ and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Low disease activity and remission in rheumatoid arthritis (RA) patients is achieved earlier and in higher frequency when the initial treatment includes a combination…
Abstract Number: 1409 • 2016 ACR/ARHP Annual Meeting
Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Marieke J. de Jonge¹, Laura W.M. Boerboom¹, Anita M.P. Huis¹, Julia M. Weijers¹, Mart A.F.J. van de Laar², Marlies E.J.L. Hulscher¹ and Piet L.C.M. van Riel^1,3, ¹Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, ²University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ³Bernhoven, Department of Rheumatology, Uden, Netherlands
Background/Purpose: International guidelines and studies recommend rheumatologists to use validated measures to monitor disease activity, such as the Disease Activity Score of 28 joints (DAS28).…
Abstract Number: 1677 • 2016 ACR/ARHP Annual Meeting
Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Andreas Kerschbaumer^1,2, Karl Fenzl², Michael Weber³, Johannes Resch⁴, Martin Kasper⁴, Daniel Aletaha⁵ and Ludwig Erlacher^4,6, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Institute for Autoimmune Diseases and Rheumatology, Karl Landsteiner Institute, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴2nd Medical Department, Department for Rheumatology, Osteology and Geriatric medicine, Sozialmedizinisches Zentrum Sued, Vienna, Austria, ⁵Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ⁶Karl Landsteiner Institute, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in a subgroup of patients suffering from psoriasis. Assessment of PsA disease activity currently mainly…
Abstract Number: 1992 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Is an Independent Risk Factor for Increased Insulin Resistance and Impaired Beta-Cell Function: Impact of Disease Activity
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in pts with rheumatoid arthritis (RA). The aim of our study was to investigate…
Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
J Fransen¹, L Tweehuysen², A den Broeder³, R Postema⁴, E Alemao⁵ and F van den Hoogen⁶, ¹Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ²Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Rheumatology, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
Abstract Number: 2728 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Renganayaki Pandurengan³, Yujin Park⁴ and Jeffrey D. Greenberg^3,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Clinical trials have demonstrated the efficacy of biologic therapy in improving the clinical and patient-reported outcomes in patients with ankylosing spondylitis (AS); however, there…
Abstract Number: 2940 • 2016 ACR/ARHP Annual Meeting
Bechet’s Disease and Sleep Quality in Korean Patients
Chang-Nam Son¹, Ji Min Lee¹, Hye-Jin Jeong², Ji-Min Kim¹, Sang-Hyon Kim¹, Sung Soo Kim³ and Seung-Hyeon Bae⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The purpose of this study was to find out the effects of sleep quality on Behcet’s disease in Korean population. We also investigated the…
Abstract Number: 450 • 2016 ACR/ARHP Annual Meeting
Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Susan J. Bartlett^1,2, Skye Barbic³, Vivian P. Bykerk⁴, Bruno Fautrel⁵, Francis Guillemin⁶, A den Broeder⁷, R Alten⁸, Robin Christensen⁹, Ernest H. Choy¹⁰, Daniel E. Furst¹¹, Sarah Hewlett¹², Amye L. Leong¹³, Lyn March¹⁴, Thasia G Woodworth¹⁵, Clifton Bingham III¹⁶ and OMERACT Flare Group and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of British Columbia, Vancouver, BC, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁶University of Lorraine, Nancy, France, ⁷Rheumatology, Maartenskliniek, Nijmegen, Netherlands, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany, ⁹The Parker instutute, RC, Copenhagen, Denmark, ¹⁰Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ¹¹University of California, Los Angeles, Los Angeles, CA, ¹²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹³Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹⁴Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁵Leading Edge Clinical Research, Stuart, FL, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: OMERACT Filter 2.0 encourages use of robust methods to develop new measures. Instrument results also should be highly relevant, easily scored and interpreted, and…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Frank Behrens¹, Tanja Rossmanith², Michaela Koehm³, Rieke Alten⁴, Martin Aringer⁵, GR Burmester⁶, Eugen Feist⁷, Klaus Krüger⁸, Ulf Müller-Ladner⁹, Andrea Rubbert-Roth¹⁰, Siegfried Wassenberg¹¹, Hans-Peter Tony¹², Herbert Kellner¹³, Marina Backhaus¹⁴ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ⁴Schlosspark-Klinik University Medicine, Berlin, Germany, ⁵Abteilung für Rheumatologie, Dresden, Germany, ⁶Charité – University Medicine Berlin, Berlin, Germany, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Praxiszentrum St. Bonifatius, München, Germany, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰Division Rheuamatology, University Köln, Köln, Germany, ¹¹Rheumazentrum, Ratingen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Rheumatology Patient Care, Munchen, Germany, ¹⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…
Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Irene Lazarus¹, Salahuddin Kazi², Alok Dwivedi³, Christopher Dodoo⁴ and Kanchan Pema⁵, ¹Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX
Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
Abstract Number: 1683 • 2016 ACR/ARHP Annual Meeting
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Renganayaki Pandurengan², Christopher T. Ritchlin⁴, Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Although spinal involvement has been well studied in ankylosing spondylitis,1 very few studies in psoriatic arthritis (PsA) have characterized patients with axial involvement. The…
Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Shafay Raheel¹, Cynthia S. Crowson², Eric L. Matteson¹ and Elena Myasoedova¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].